|Articles|June 1, 2012

Applied Clinical Trials-06-01-2012
Volume 21
Issue 6

Applied Clinical Trials Digital Edition - June 2012

CRO/Sponsor: Comparative Effectiveness Research and Precision Healthcare Pharmacovigilance Outsourcing: A Guide Survey: Negotiating a Clinical Trial Agreement Also in this issue: Trial Modernization EMA Under Attack Too Much Data? Community Portals

External Link - 2012-06ACT2.pdf

Articles in this issue

over 14 years ago

Article

Survey Reveals Patient Recruitment is the Biggest Challenge in Pediatric Trials

over 14 years ago

Article

ACT Cover

over 14 years ago

Article

Clinical Trial Agreement Negotiations

over 14 years ago

Article

Buckthorn Wars and the Essence of Clinical Data

over 14 years ago

Article

European Medicines Agency Under Attack

over 14 years ago

Article

Personalized Healthcare

over 14 years ago

Article

Pharmacovigilance Outsourcing: A Guide

over 14 years ago

Article

Standard of Care Billing More Widespread

over 14 years ago

Article

What Do More Complex eCRFs Mean for Clinical Research

over 14 years ago

Article

Phones Still a Vital Part of Clinical Research

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

October 2nd, 2026

What ClinOps Professionals Just Starting With AI Should Keep Top of Mind

In this video interview, Claire Riches, VP of clinical solutions at Citeline, offers practical guidance for clinical operations teams beginning their AI journey—making the case that the tools are more accessible than many assume and that waiting to start is a competitive risk in itself.

October 2nd, 2026

ACT Brief: Proactive Trial Risk Management, Federal Infrastructure Modernization, Pediatric Heart Disease Treatment

In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.

© Tada Images - © Tada Images - stock.adobe.com

October 1st, 2026

HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure

The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.

October 1st, 2026

What an AI-Informed Approach Means for How Sponsors Think About Risk

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.

October 1st, 2026

ACT Brief: AI as Design Advisor, Autonomous Agent Governance, Oral Weight-Loss Therapy Switch

In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.

September 30th, 2026

The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials

AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.

September 30th, 2026

Where AI Leads in Trial Design—and Where Humans Still Need To

In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.

September 30th, 2026

ACT Brief: Enrollment Feasibility Pressure-Testing, RWE Infrastructure Gaps, and Peptide Rulemaking Standstill

In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.